Integrating Genetics into Endometrial Cancer Clinical Practice

Speakers:

• Amanda Nickles Fader, MD, Johns Hopkins Medical Institutions, Baltimore, MD
• Alessandro Santin, MD, Yale University School of Medicine, New Haven, CT

Description: After attending the session, participants will be able to better understand the genetic classification of endometrial cancer and identify the tumor genetic characteristics of MSI-H hypermutated and HER2/neu amplified copy-number high endometrial cancer patients correlated with responsiveness to immune check point inhibitors and anti-HER2/neu targeted treatment (i.e., trastuzumab), respectively.

Learning Objectives:

• Review the TCGA molecular classifications of endometrial carcinoma and implications for treatment.
• Discuss the rationale for immunotherapy in the treatment of women with ultra/hypermutated, MSI-H and non-mutated endometrial cancer.
• Appraise the use of targeted treatment in a number of high serous-like endometrial cancer patients.